On Friday, Bond yields climbed, with the U.S. 10-year Treasury note yield at 2.20%, on raised anticipation of an interest rate hike sooner rather than later. The U.S. dollar climbed 1 percent against major world currencies.

Trade balance data for January showed $41.75 billion, a decrease from December’s $45.60 billion.

Following U.S. stocks are among the top gainers in the recent trade: AVEO Pharmaceuticals, Inc (NASDAQ:AVEO), Aoxing Pharmaceutical Company, Inc (NYSEMKT:AXN), EXACT Sciences Corporation (NASDAQ:EXAS),Second Sight Medical Products Inc (NASDAQ:EYES)

Their insights are depicted underneath:

AVEO Pharmaceuticals, Inc (NASDAQ:AVEO)’s shares the stock skyrocketed 34.35%, and is now trading at $1.91, hitting new 52-week high of $2.02.

AVEO Pharmaceuticals, Inc. (AVEO), stated financial results for the full year ended December 31, 2014.

Recent Highlights:

• Declared Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib as compared to Bevacizumab in Low Serum NRP-1 Patients with Advanced CRC – Recently, AVEO declared the presentation of final results, counting a predefined biomarker analysis, from the BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC). The presentation, titled “Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 as compared to bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial,” will be presented in a poster session recently at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference, taking place March 5-8, 2015, in Orlando, FL.
• Named Michael P. Bailey as President and Chief Executive Officer – In January 2015, AVEO declared that its board of directors designated Michael P. Bailey as the Corporation’s president and chief executive officer and has elected Mr. Bailey as a director. Mr. Bailey succeeds Tuan Ha-Ngoc, who was named chairman of AVEO’s board of directors.

AVEO Oncology (AVEO) is a biopharmaceutical corporation committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes where noteworthy unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that AVEO is seeking to leverage in the clinical development strategy of its therapeutic candidates.

Aoxing Pharmaceutical Company, Inc (NYSEMKT:AXN), raised 8.93%, and is now trading at $1.22.

Formerly on February 17, Aoxing Pharmaceutical Company, Inc. (AXN), a specialty pharmaceutical corporation focusing on research, development, manufacturing, and distribution of narcotic, pain-administration, and addiction treatment pharmaceuticals, declared its financial and operational results for the quarter ended December 31, 2014.

Second Quarter 2015 Highlights:

Proceeds in the second quarter raised 85% year over year to $6.4 million while cost of sales reduced 20% year over year to $1.6 million. Gross profit for the second quarter was $4.8 million, representing a 75% gross margin, and an raise of 233% as contrast to the same quarter last year.

Net profit for the second quarter was $0.6 million instead of a net loss of $1.9 million for the same quarter last year.

Net cash generated from operating activities for the six months ended December 31, 2014 was $3.4 million contrast to the use of $2.8 million cash in operations for the period ended December 31, 2013.

Basic and diluted revenue per ordinary share were both $0.01 for the second quarter as contrast to net loss of ($0.04) per basic and diluted share for the same quarter last year.

Aoxing Pharmaceutical Corporation, Inc. is a US incorporated specialty pharmaceutical corporation with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-administration products.

EXACT Sciences Corporation (NASDAQ:EXAS), enhanced 10.86%, and is now trading at $24.86.

Exact Sciences Corporation (EXAS), declared that Aetna, one of the country’s leading health plans, will cover Cologuard under its Medicare Advantage plan, reaching 967,000 members across the country. The three year contract will go into effect on April 1, 2015.

Cologuard is the first and only FDA approved noninvasive stool-based DNA (sDNA) screening test for colon cancer. The test will be accessible to Aetna’s Medicare Advantage members through their physician without a co-payment or co-insurance.

Cologuard offers people 50 years and older who are at average risk for colorectal cancer an easy to use screening test which they can do in the privacy of their own home. Unlike many other screening options, Cologuard does not require medication, dietary restrictions or bowel preparation preceding to taking the test. It is the first noninvasive screening test for colorectal cancer that analyzes both sDNA and blood biomarkers to detect cancer and precancer. Cologuard is accessible by prescription only.

Exact Sciences Corp. (EXAS) is a molecular diagnostics corporation focused on the early detection and prevention of colorectal cancer. The corporation has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Cologuard is comprised of in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is comprised of in the U.S. Multi-Society Task Force on Colorectal Cancer.

Second Sight Medical Products Inc (NASDAQ:EYES), rose 3.22%, and is now trading at $17.62.

Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, declared that two newly approved centers, located in Camposampiero and Florence, have successfully accomplished their first commercial implants of the Argus II Retinal Prosthesis System (“Argus II”) in patients with outer retinal degeneration.

Outer retinal degeneration is the deterioration of the outer layer of the retina caused by progressive death of the cells in this region of the retina. An important type of outer retinal degeneration is Retinitis Pigmentosa (RP), which is a rare, hereditary disease that causes a progressive degeneration of the light-sensitive cells of the retina, leading to noteworthy visual impairment and ultimately can lead to blindness. There are an estimated 2,200 people in Italy, and 167,000 persons across Europe with RP in total.

Second Sight Medical Products, Inc. was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations such as RP. Second Sight’s mission is to develop, manufacture, and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence.